Class: ACEI/Thiazide Diuretic Combination
Dosage Forms. Tablet: Benazepril/Hydrochlorothiazide 5 mg/6.25 mg, 10 mg/12.5 mg, 20 mg/12.5 mg, 20 mg/25 mg
Common FDA Label Indication, Dosing, and Titration.
1. Hypertension: 10-20 mg benazepril/12.5-25 mg hydrochlorothiazide po daily
Off-Label Uses. None
MOA. Benazepril is a competitive ACE inhibitor. Thiazides increase sodium and chloride excretion by interfering with their reabsorption in the cortical diluting segment of the nephron; a mild diuresis of slightly concentrated urine results.
Drug Characteristics: Benazepril/Hydrochlorothiazide
Medication Safety Issues: Benazepril/Hydrochlorothiazide
Drug Interactions: Benazepril/Hydrochlorothiazide
Adverse Reactions: Benazepril/Hydrochlorothiazide
Efficacy Monitoring Parameters. BP.
Toxicity Monitoring Parameters. Signs/symptoms of angioedema (swelling of the face, eyes, lips, tongue, or throat), severe persistent cough, hypotension; monitor baseline and periodic electrolytes, SCr, BUN, and urine protein.
Key Patient Counseling Points. Avoid pregnancy. Avoid sudden discontinuation; rebound hypertension can occur. Use potassium supplements or salt substitutes only under medical supervision. May cause dizziness that may worsen if dehydrated.
Clinical Pearls. Safety and efficacy not established in pediatric patients. Observe patients who are volume depleted for at least 2 h after taking the initial dose.